Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Ito

Showing results (161-170 of 191) with videos related to

Pageof 20
Sort By:
Hematology Reports|October 4, 2019
A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptomsTakahisa Nakanishi, Aya Nakaya, Yusuke Nishio, et al.
Science Translational Medicine|March 11, 2011
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosusRoberto Lande, Dipyaman Ganguly, Valeria Facchinetti, et al.
International Journal of Hematology|April 25, 2020
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/dayYoshinori Hashimoto, Tomoki Ito, Yasuhiro Tanaka, et al.
European Journal of Haematology|May 21, 2019
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world settingTomoki Ito, Yoshinori Hashimoto, Yasuhiro Tanaka, et al.
Journal of Surgical Case Reports|January 8, 2026
Neoantigen dendritic cell vaccination combined with conventional chemotherapy for a patient with advanced transverse colon cancerHideya Onishi, Atsushi Higa, Mayu Tasaki, et al.
International Journal of Hematology|March 8, 2024
Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in JapanKensuke Usuki, Takuro Kameda, Noriaki Kawano, et al.
Biochemical and Biophysical Research Communications|June 15, 2010
Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and miceChihiro Yamazaki, Rie Miyamoto, Katsuaki Hoshino, et al.
Future Oncology (London, England)|February 29, 2024
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)Yu Abe, Shiro Kubonishi, Masaki Ri, et al.
European Journal of Haematology|March 17, 2022
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international studyTomoki Ito, David Sanford, Ciprian Tomuleasa, et al.
Annals of Hematology|August 21, 2024
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patientsYutaka Shimazu, Junya Kanda, Teruhito Takakuwa, et al.
Pageof 20

Showing results (161-170 of 191) with videos related to

Sort By:
Pageof 20
Hematology Reports|October 4, 2019
A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptomsTakahisa Nakanishi, Aya Nakaya, Yusuke Nishio, et al.
Science Translational Medicine|March 11, 2011
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosusRoberto Lande, Dipyaman Ganguly, Valeria Facchinetti, et al.
International Journal of Hematology|April 25, 2020
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/dayYoshinori Hashimoto, Tomoki Ito, Yasuhiro Tanaka, et al.
European Journal of Haematology|May 21, 2019
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world settingTomoki Ito, Yoshinori Hashimoto, Yasuhiro Tanaka, et al.
Journal of Surgical Case Reports|January 8, 2026
Neoantigen dendritic cell vaccination combined with conventional chemotherapy for a patient with advanced transverse colon cancerHideya Onishi, Atsushi Higa, Mayu Tasaki, et al.
International Journal of Hematology|March 8, 2024
Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in JapanKensuke Usuki, Takuro Kameda, Noriaki Kawano, et al.
Biochemical and Biophysical Research Communications|June 15, 2010
Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and miceChihiro Yamazaki, Rie Miyamoto, Katsuaki Hoshino, et al.
Future Oncology (London, England)|February 29, 2024
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)Yu Abe, Shiro Kubonishi, Masaki Ri, et al.
European Journal of Haematology|March 17, 2022
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international studyTomoki Ito, David Sanford, Ciprian Tomuleasa, et al.
Annals of Hematology|August 21, 2024
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patientsYutaka Shimazu, Junya Kanda, Teruhito Takakuwa, et al.
Pageof 20